WaferGen Appoints Seasoned Industry Executives to Board of Directors and Scientific Advisory Board
Also Announces Chief Operating Officer Promotion
“We believe that we have significantly strengthened the leadership team at WaferGen with the additions of Drs. Hariri and McBride. Through careers marked by achievement, these gentlemen have distinguished themselves as highly-regarded life science executives and we are pleased to count them among the many talented individuals that comprise our management team, board of directors and scientific advisory board,” stated
Dr. Hariri has served as the chief executive officer of Celgene Cellular Therapeutics, a division of Celgene Corporation (Nasdaq: CELG), since 2005. Prior to joining Celgene Cellular Therapeutics as president in 2002, Dr. Hariri was founder, chairman and chief scientific officer at Anthrogenesis Corporation/LIFEBANK, Inc., a privately held biomedical technology and service corporation involved in the area of human stem cell therapeutics, which was acquired by Celgene in 2002. He has also served as co-founder, vice chairman and chief scientific officer of Neurodynamics, a privately held medical device and technology corporation. Dr. Hariri has also held key academic positions at
As a scientist and life science executive with nearly 30 years of experience including work in the area of real-time PCR, Dr. McBride has proven expertise in commercializing several breakthrough enabling technologies for life science research. His work has included tenures with leading enabling technology companies such as Applied BioSystems, Perkin Elmer and Fluidigm. While at Fluidigm, during which time he served as vice president of research and development and chief technology officer, Dr. McBride is credited with leading the commercialization of the TOPAZ(R) System, the company’s first product line and the world’s first chip-based product for structural biology. Previously, Dr. McBride oversaw the marketing and scientific collaboration between Perkin Elmer and Applied Biosystems prior to the merger of the two companies. During this period, he founded and led the companies’ effort to commercialize the world’s first real-time PCR system. As an author, Dr. McBride is credited with more than 25 journal publications, six issued U.S. patents and numerous U.S. patent applications.
Prior to her promotion,
WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genetic analysis for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time PCR platform. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker discovery and validation. WaferGen currently markets its SmartSlide(TM) family of products to companies and organizations involved in stem cell and cell biology research. SmartSlide represents the first fluidics integrated micro-incubators enabling cell biology and stem cell research.
This press release contains certain “forward-looking statements”. Such statements include statements relating to the recent strengthening of the leadership team of the company and other statements relating to future events or to the company’s future financial performance and are not historical facts, including statements which may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company’s proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K for the year ended
Contact: Vida Communication (Media) The Trout Group (Investors) On Behalf of WaferGen On Behalf of WaferGen Tim Brons Peter Rahmer 415-675-7400 646-378-2973 email@example.com San Francisco, CA or Christine Yang 646-378-2929 New York, NY
SOURCE WaferGen Biosystems, Inc.